NCT05536102View on ClinicalTrials.gov

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 5, 2022

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2027

Conditions
Gastric Cancer
Interventions
DRUG

PLD

20mg/m2, day 1, q3w

DRUG

Oxaliplatin

130 mg/m2, day 1, q3w

DRUG

Capecitabine

1000 mg/m2, days 1-14, q3w

DRUG

Tislelizumab

200 mg, day 1, q3w

Trial Locations (1)

200080

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER